Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes

Ophthalmology
Kunyong XuDavid R P Almeida

Abstract

We describe the presentation of patients developing endophthalmitis after intravitreal injection with vascular endothelial growth factor (VEGF) inhibitors. Moreover, we evaluate the management by comparing the outcomes of immediate tap and injection of intravitreal antibiotics (TAI) versus initial surgical pars plana vitrectomy (PPV). Finally, we analyze the predictive factors of visual outcomes at 6-month follow-up. Retrospective, single-center, nonrandomized interventional study. Patients developing endophthalmitis after receiving an intravitreal injection of anti-VEGF agent between 2006 and 2016. All patients received a vitreous biopsy sent for cultures before the initiation of treatment: TAI group versus PPV with intravitreal antibiotics (PPV group). Best-corrected visual acuity (BCVA) at 6-month follow-up after treatment for endophthalmitis. A total of 258 357 intravitreal injections occurred over the course of the 10-year period, of which 40 patients (0.016%) had endophthalmitis within 3 weeks after injection. In total, 34 patients (85.0%) had pain and 25 patients (62.5%) had hypopyon on initial examination. Among 24 culture-positive cases, 66.7% of the causative organisms were coagulase-negative Staphylococcus, followed ...Continue Reading

Associated Clinical Trials

Citations

Jan 15, 2019·Ophthalmic Surgery, Lasers & Imaging Retina·Joseph M SimonettChristina J Flaxel
Mar 5, 2019·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Reas S KhanKenneth S Shindler
Jan 25, 2020·Journal of Glaucoma·Jeffrey M LiebmannE Randy Craven
Aug 4, 2020·Translational Vision Science & Technology·Tilvawala GopeshRobert N Weinreb
Apr 12, 2020·BMC Ophthalmology·Danny A MammoKaren R Armbrust
Aug 5, 2018·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·L-J DammK Januschowski
Nov 14, 2018·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·A ChronopoulosL-O Hattenbach
May 8, 2020·Journal of Ophthalmology·Claudio FurinoGiovanni Alessio
Jun 17, 2020·Ophthalmology Retina·Ryan A ShieldsTarek S Hassan
Feb 9, 2021·American Journal of Ophthalmology Case Reports·Robert L SteinmetzHarry W Flynn
Nov 18, 2020·BMC Infectious Diseases·Xin CheZhiliang Wang
Mar 29, 2020·American Journal of Ophthalmology·Cecilia S LeeUNKNOWN Endophthalmitis Study Group
Dec 16, 2018·American Journal of Ophthalmology·Philip P StoreyUNKNOWN Post-Injection Endophthalmitis (PIE) Study Group
Oct 16, 2020·Ophthalmology Retina·Michael S RamosAmy S Nowacki
Jun 1, 2021·Case Reports in Ophthalmological Medicine·Lisa PohlFocke Ziemssen
Jun 30, 2021·Ophthalmic Surgery, Lasers & Imaging Retina·Daniela P Reyes-CapoUNKNOWN Endophthalmitis/Anti-VEGF Study Group*

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.